Literature DB >> 17327227

Phosphorylation of Parkin by the cyclin-dependent kinase 5 at the linker region modulates its ubiquitin-ligase activity and aggregation.

Eyal Avraham1, Ruth Rott, Esti Liani, Raymonde Szargel, Simone Engelender.   

Abstract

Mutations in Parkin are responsible for a large percentage of autosomal recessive juvenile parkinsonism cases. Parkin displays ubiquitin-ligase activity and protects against cell death promoted by several insults. Therefore, regulation of Parkin activities is important for understanding the dopaminergic cell death observed in Parkinson disease. We now report that cyclin-dependent kinase 5 (Cdk5) phosphorylates Parkin both in vitro and in vivo. We found that highly specific Cdk5 inhibitors and a dominant negative Cdk5 construct inhibited Parkin phosphorylation, suggesting that a significant portion of Parkin is phosphorylated by Cdk5. Parkin interacts with Cdk5 as observed by co-immunoprecipitation experiments of transfected cells and rat brains. Phosphorylation by Cdk5 decreased the auto-ubiquitylation of Parkin both in vitro and in vivo. We identified Ser-131 located at the linker region of Parkin as the major Cdk5 phosphorylation site. The Cdk5 phosphorylation-deficient S131A Parkin mutant displayed a higher auto-ubiquitylation level and increased ubiquitylation activity toward its substrates synphilin-1 and p38. Additionally, the S131A Parkin mutant more significantly accumulated into inclusions in human dopaminergic cells when compared with the wild-type Parkin. Furthermore, S131A Parkin mutant increased the formation of synphilin-1/alpha-synuclein inclusions, suggesting that the levels of Parkin phosphorylation and ubiquitylation may modulate the formation of inclusion bodies relevant to the disease. The data indicate that Cdk5 is a new regulator of the Parkin ubiquitin-ligase activity and modulates its ability to accumulate into and modify inclusions. Phosphorylation by Cdk5 may contribute to the accumulation of toxic Parkin substrates and decrease the ability of dopaminergic cells to cope with toxic insults in Parkinson disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17327227     DOI: 10.1074/jbc.M608243200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  48 in total

Review 1.  Regulation of Parkin E3 ubiquitin ligase activity.

Authors:  Helen Walden; R Julio Martinez-Torres
Journal:  Cell Mol Life Sci       Date:  2012-04-19       Impact factor: 9.261

2.  Parkin-catalyzed ubiquitin-ester transfer is triggered by PINK1-dependent phosphorylation.

Authors:  Masahiro Iguchi; Yuki Kujuro; Kei Okatsu; Fumika Koyano; Hidetaka Kosako; Mayumi Kimura; Norihiro Suzuki; Shinichiro Uchiyama; Keiji Tanaka; Noriyuki Matsuda
Journal:  J Biol Chem       Date:  2013-06-10       Impact factor: 5.157

Review 3.  Cdk5: mediator of neuronal development, death and the response to DNA damage.

Authors:  Jinqiu Zhu; Wenming Li; Zixu Mao
Journal:  Mech Ageing Dev       Date:  2011-05-11       Impact factor: 5.432

Review 4.  The c-Abl inhibitor in Parkinson disease.

Authors:  Zhi-Hua Zhou; Yun-Fan Wu; Xue-Min Wang; Yong-Zhu Han
Journal:  Neurol Sci       Date:  2017-01-11       Impact factor: 3.307

5.  CDK5-Mediated Phosphorylation-Dependent Ubiquitination and Degradation of E3 Ubiquitin Ligases GP78 Accelerates Neuronal Death in Parkinson's Disease.

Authors:  Qingzhi Wang; Fengjuan Jiao; Pei Zhang; Jianguo Yan; Zheng Zhang; Feng He; Qian Zhang; Zexi Lv; Xiang Peng; Hongwei Cai; Bo Tian
Journal:  Mol Neurobiol       Date:  2017-05-20       Impact factor: 5.590

Review 6.  Deregulated Cdk5 activity is involved in inducing Alzheimer's disease.

Authors:  Varsha Shukla; Susan Skuntz; Harish C Pant
Journal:  Arch Med Res       Date:  2012-11-07       Impact factor: 2.235

7.  Parkin ubiquitinates Tar-DNA binding protein-43 (TDP-43) and promotes its cytosolic accumulation via interaction with histone deacetylase 6 (HDAC6).

Authors:  Michaeline L Hebron; Irina Lonskaya; Kaydee Sharpe; Puwakdandawe P K Weerasinghe; Norah K Algarzae; Ashot R Shekoyan; Charbel E-H Moussa
Journal:  J Biol Chem       Date:  2012-12-20       Impact factor: 5.157

Review 8.  Programmed cell death in Parkinson's disease.

Authors:  Katerina Venderova; David S Park
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

Review 9.  An emerging role of PARK2 in cancer.

Authors:  Liang Xu; De-chen Lin; Dong Yin; H Phillip Koeffler
Journal:  J Mol Med (Berl)       Date:  2013-12-03       Impact factor: 4.599

Review 10.  Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration.

Authors:  P S Vosler; C S Brennan; J Chen
Journal:  Mol Neurobiol       Date:  2008-08-07       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.